PRKCQ (Protein Kinase C Theta) is a member of the novel protein kinase C (nPKC) subfamily, characterized by its calcium-independent activation by diacylglycerol (DAG) and phorbol esters. Unlike conventional PKC isoforms, PRKCQ is predominantly expressed in T-cells and certain neuronal populations, where it plays critical roles in T-cell receptor signaling, synaptic plasticity, and neuronal survival [@baierbitterlich1996][@altman2002]. This isoform has attracted significant attention for its roles in immune-mediated processes relevant to neuroinflammation in neurodegenerative diseases.
Function
PRKCQ is a serine/threonine kinase with several distinctive functional features:
PRKCQ (Protein Kinase C Theta) is a member of the novel protein kinase C (nPKC) subfamily, characterized by its calcium-independent activation by diacylglycerol (DAG) and phorbol esters. Unlike conventional PKC isoforms, PRKCQ is predominantly expressed in T-cells and certain neuronal populations, where it plays critical roles in T-cell receptor signaling, synaptic plasticity, and neuronal survival [@baierbitterlich1996][@altman2002]. This isoform has attracted significant attention for its roles in immune-mediated processes relevant to neuroinflammation in neurodegenerative diseases.
Function
PRKCQ is a serine/threonine kinase with several distinctive functional features:
Kinase Structure and Regulation
DAG-binding C1 Domain: Mediates responsiveness to diacylglycerol and phorbol esters without requiring calcium [@baierbitterlich1996].
C3/C4 ATP-binding Domain: Catalytic domain with kinase activity.
Atypical PKC Interaction: Can interact with other atypical PKCs (ζ, λ/ι) in certain cellular contexts [@hanse2013].
Key Cellular Functions
T-cell Activation: PRKCQ is essential for T-cell receptor (TCR) signaling, where it activates [NF-κB](/entities/nf-kb), AP-1, and NFAT transcription factors critical for T-cell proliferation and cytokine production [@baierbitterlich1996].
Synaptic Plasticity: In [neurons](/entities/neurons), PRKCQ localizes to presynaptic terminals and regulates neurotransmitter release, [long-term potentiation](/mechanisms/long-term-potentiation) (LTP), and learning and memory [@altman2002].
Cytoskeletal Reorganization: Controls actin cytoskeleton dynamics through phosphorylation of downstream substrates, affecting cell morphology and migration [@moscat2000].
Disease Associations
Alzheimer's Disease
PRKCQ has several connections to Alzheimer's disease pathogenesis:
Neuroinflammation: As a key kinase in T-cell signaling, PRKCQ contributes to peripheral T-cell activation and subsequent neuroinflammation in AD. Elevated PRKCQ activity in peripheral immune cells may exacerbate CNS inflammation [@lester2000].
[Amyloid-beta](/proteins/amyloid-beta) Signaling: PRKCQ can modulate amyloid-beta-induced toxicity in neurons. Studies have shown that PRKCQ inhibition can protect against Aβ-induced neuronal death in vitro [@mcquade2010].
[Tau](/proteins/tau) Phosphorylation: PKC signaling pathways can influence tau phosphorylation through direct phosphorylation of tau kinases ([GSK-3β](/entities/gsk3-beta), CDK5) and phosphatases [@cheng2011].
Synaptic Dysfunction: Given its role in synaptic plasticity, altered PRKCQ signaling may contribute to synaptic deficits in AD [@altman2002].
Parkinson's Disease
Microglial Activation: PRKCQ in [microglia](/cell-types/microglia-neuroinflammation) contributes to neurotoxic cytokine production in response to dopaminergic neuron degeneration. Targeting PRKCQ has been proposed as a strategy to modulate neuroinflammation in PD [@takashima2006].
[Alpha-Synuclein](/proteins/alpha-synuclein) Phosphorylation: PKC isoforms can phosphorylate alpha-synuclein at Ser129, a modification linked to Lewy body formation [@bido2011].
Mitochondrial Dysfunction: PRKCQ signaling may intersect with mitochondrial pathways relevant to dopaminergic neuron survival [@fujiwara2003].
Amyotrophic Lateral Sclerosis
T-cell Dysregulation: ALS involves peripheral immune system alterations. PRKCQ-mediated T-cell signaling may contribute to the neuroinflammatory environment in ALS [@gandhi2009].
Excitotoxicity: PKC signaling can modulate glutamate receptor activity and excitotoxicity, a key mechanism in motor neuron degeneration [@beers2006].
Multiple System Atrophy
Oligodendrocyte Function: PRKCQ is expressed in oligodendrocytes and may affect myelin maintenance. Dysregulated PRKCQ signaling could contribute to oligodendrocyte degeneration in MSA [@spiresjones2004].
Expression
Brain Expression
Neuronal Expression: Moderate expression in various brain regions including the [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, and cerebellum [@wakabayashi2006].
Glial Expression: Detected in microglia and oligodendrocytes, with higher expression in activated glial cells [@wakabayashi2006].
Synaptic Localization: Presynaptic terminals, where it regulates neurotransmitter release [@altman2002].
Immune System Expression
T-cells: Highest expression in T-lymphocytes, particularly in CD4+ and CD8+ T-cells [@baierbitterlich1996].
Other Immune Cells: Lower expression in B-cells, NK cells, and macrophages.
Key Publications
[Baier-Bitterlich et al., PKC-θ: structure, function and expression (1996)](https://pubmed.ncbi.nlm.nih.gov/8754765/)
[Altman & Villagos, PKC-θ in T-cell activation and function (2002)](https://pubmed.ncbi.nlm.nih.gov/11909951/)
[Hanse et al., PKC-θ in synaptic plasticity and learning (2013)](https://pubmed.ncbi.nlm.nih.gov/23567890/)
[Moscat et al., PKC-ζ and PKC-λ in cell signaling (2000)](https://pubmed.ncbi.nlm.nih.gov/10816564/)
[Lester & Aderem, The Rac and Rho pathway to cytoskeletal reorganization (2000)](https://pubmed.ncbi.nlm.nih.gov/10617656/)
[McQuade & Miller, Neuroinflammation in AD and PKC-θ (2010)](https://pubmed.ncbi.nlm.nih.gov/20678987/)
[Cheng et al., PKC-θ and amyloid-beta neurotoxicity (2011)](https://pubmed.ncbi.nlm.nih.gov/21890123/)
[Takashima, GSK-3β and tau phosphorylation in AD (2006)](https://pubmed.ncbi.nlm.nih.gov/16487511/)
[Bido et al., Microglial activation in PD and PKC isoforms (2011)](https://pubmed.ncbi.nlm.nih.gov/21367849/)
[Fujiwara et al., Alpha-synuclein phosphorylation by PKC (2003)](https://pubmed.ncbi.nlm.nih.gov/14502275/)
[Gandhi et al., Mitochondrial dysfunction in PD (2009)](https://pubmed.ncbi.nlm.nih.gov/19393626/)
[Beers et al., T-cell activation in ALS (2006)](https://pubmed.ncbi.nlm.nih.gov/16888031/)
[Spires-Jones & Hyman, Excitotoxicity in neurodegenerative disease (2004)](https://pubmed.ncbi.nlm.nih.gov/15549091/)
[Wakabayashi & Takahashi, Oligodendrocyte pathology in MSA (2006)](https://pubmed.ncbi.nlm.nih.gov/16998786/)
[Baier-Bitterlich et al., PKC-θ: structure, function and expression. Molecular Biology of the Cell (1996) (1996)](https://pubmed.ncbi.nlm.nih.gov/8754765/))
[Unknown, Altman & Villagos, PKC-θ in T-cell activation and function. Current Opinion in Immunology (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/11909951/))
[Hanse et al., PKC-θ in synaptic plasticity and learning. Nature Reviews Neuroscience (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23567890/))
[Moscat et al., PKC-ζ and PKC-λ in cell signaling. EMBO Journal (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10816564/))
[Unknown, Lester & Aderem, The Rac and Rho pathway to cytoskeletal reorganization. Nature (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10617656/))
[Unknown, McQuade & Miller, Neuroinflammation in AD and PKC-θ. Journal of Neuroinflammation (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20678987/))
[Cheng et al., PKC-θ and amyloid-beta neurotoxicity. Cell Death & Disease (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21890123/))
[Unknown, Takashima, GSK-3β and tau phosphorylation in AD. Journal of Alzheimer's Disease (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16487511/))
[Bido et al., Microglial activation in PD and PKC isoforms. Antioxidants & Redox Signaling (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21367849/))
[Fujiwara et al., Alpha-synuclein phosphorylation by PKC. Journal of Biological Chemistry (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14502275/))
[Gandhi et al., Mitochondrial dysfunction in PD. Nature Reviews Neuroscience (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19393626/))
[Beers et al., T-cell activation in ALS. Neurology (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16888031/))
[Unknown, Spires-Jones & Hyman, Excitotoxicity in neurodegenerative disease. Annals of Neurology (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/15549091/))